E
EpiBiologics
United States · Biotech
Develops bispecific antibodies for targeted degradation of extracellular proteins.
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Series B | $107M | Aulis Capital — Role not disclosedAvego BioScience Capital — Role not disclosedCodon Capital — Role not disclosedDigitalis Ventures — Role not disclosedGV (Google Ventures) — Role not disclosedInc — Role not disclosedJohnson & Johnson Innovation – JJDC — Role not disclosedMission BioCapital — Role not disclosedNovartis Venture Fund (NVF) — Role not disclosedPolaris Partners — Role not disclosedSamsara BioCapital — Role not disclosedTaiho Ventures — Role not disclosedVivo Capital — Role not disclosed |